DAPA VILDA 5/100 SR

Description

DAPA VILDA 5/100 SR is a combination medication specially formulated for the management of type 2 diabetes mellitus in adults. It combines two active ingredients, dapagliflozin (5mg) and vildagliptin sustained-release (SR) (100mg), each targeting different pathways in glucose regulation to provide comprehensive glycemic control. This dual-action approach not only helps reduce elevated blood sugar levels but also supports weight management and cardiovascular health. DAPA VILDA 5/100 SR is designed to be taken once daily as part of a complete diabetes management plan that includes diet, exercise, and possibly other diabetic medications. Vildagliptin and dapagliflozin tablets are used to treat type 2 diabetes. Dapagliflozin helps remove excess glucose through urine, while vildagliptin increases insulin secretion and reduces glucose production by the liver. This synergy improves blood sugar regulation and reduces diabetes-related complications. What is DAPA VILDA 5/100 SR? DAPA VILDA 5/100 SR is a fixed-dose tablet that combines dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor in sustained-release form. The combination targets multiple aspects of blood glucose control by increasing urinary glucose excretion and enhancing insulin secretion while suppressing harmful glucose production in the liver. This medication offers a balanced, efficient approach to managing type 2 diabetes symptoms. Uses of DAPA VILDA 5/100 SR DAPA VILDA 5/100 SR is mainly prescribed to: Manage blood sugar levels in adults with type 2 diabetes mellitus. Improve overall glycemic control when diet and exercise alone are insufficient. Aid in the reduction of HbA1c levels to help prevent diabetes-related complications. Support weight loss and improve cardiovascular parameters like blood pressure. Reduce the risk of complications associated with diabetes such as heart and kidney issues. Work as combination therapy either alone or with other antidiabetic medications for enhanced effectiveness. Side Effects of DAPA VILDA 5/100 SR Some common side effects experienced may include: Urinary tract infections (UTIs) Genital fungal infections Nausea or upset stomach Headache and dizziness Increased urination frequency More serious but less common side effects can include: Risk of dehydration and electrolyte imbalance Ketoacidosis (a serious condition caused by high ketones) Pancreatitis or severe abdominal pain Allergic reactions like rash, itching, or swelling Patients should monitor for symptoms and report any severe or persistent side effects to their healthcare provider promptly. Precautions Before Using DAPA VILDA 5/100 SR Before starting this medication, consider the following precautions: Inform your doctor about any history of kidney or liver disease. Notify your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. Disclose all current medications to prevent potential drug interactions. Maintain proper hydration and regularly monitor kidney function. Avoid use if allergic to dapagliflozin, vildagliptin, or any other components of the tablet. Use caution in elderly patients or those with low blood pressure as risk of dizziness and dehydration is higher. Drug Interactions: What Drugs Interact with DAPA VILDA 5/100 SR? DAPA VILDA 5/100 SR can interact with certain medications that may influence its effectiveness or increase the risk of adverse effects: Other antidiabetic medications (such as insulin or sulfonylureas): May increase risk of hypoglycemia (low blood sugar). Diuretics (water pills): Increased risk of dehydration and electrolyte imbalance. Rifampicin or other enzyme inducers: May reduce the effectiveness of vildagliptin. Drugs affecting kidney function: Could alter dapagliflozin’s pharmacological effects. Caution should also be used when combined with medications that impact blood pressure or heart function. Always consult your healthcare provider before starting new medications or supplements. Conclusion DAPA VILDA 5/100 SR offers an advanced and effective approach to managing type 2 diabetes by combining dapagliflozin and vildagliptin in a single sustained-release tablet. By targeting different mechanisms in glucose regulation, it helps lower blood sugar levels, control HbA1c, and reduce the risk of complications related to diabetes. Patients must use this medication under medical supervision, observe necessary precautions, and be aware of potential side effects and drug interactions. When integrated into a broader diabetes care plan that includes lifestyle modifications, DAPA VILDA 5/100 SR can significantly contribute to improved quality of life and long-term health outcomes for individuals with type 2 diabetes.